Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jun;11(2):238-41.
doi: 10.1208/s12248-009-9100-9. Epub 2009 Apr 21.

Workshop report and follow-up--AAPS Workshop on current topics in GLP bioanalysis: Assay reproducibility for incurred samples--implications of Crystal City recommendations

Douglas M Fast  1 , Marian Kelley, C T Viswanathan, Jacqueline O'Shaughnessy, S Peter King, Ajai Chaudhary, Russell Weiner, Anthony J DeStefano, Daniel Tang
Affiliations
Review

Workshop report and follow-up--AAPS Workshop on current topics in GLP bioanalysis: Assay reproducibility for incurred samples--implications of Crystal City recommendations

Douglas M Fast et al. AAPS J. 2009 Jun.

Abstract

The Conference Report of the 3rd AAPS/FDA Bioanalytical Workshop (Crystal City III) endorsed the concept that assay methods supporting bioanalytical data in submissions must demonstrate assay reproducibility by using incurred samples. The present Workshop was convened to provide a forum for discussion and consensus building about incurred sample assay reproducibility for both nonclinical and clinical studies. Information about current regulatory perspectives on incurred sample reanalysis (ISR) was presented, implications of ISR for both large and small molecules were discussed, and the steering committee put forth recommendations for performing ISR. These recommendations from the Workshop, along with the subsequent evolution of approaches leading to a robust ISR program, may be used by scientists performing bioanalytical assays for regulated studies to provide additional confirmation of assay reproducibility for incurred samples.

PubMed Disclaimer

References

    1. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG, Weiner R. Workshop/Conference Report—Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays. AAPS Journal. 2007;9(1):E30–E42. doi: 10.1208/aapsj0901004. - DOI - PubMed
    1. Fast D, Kavetskaia O, Macrae P, Steenwyk R. A Pfizer process for demonstrating assay reproducibility in GLP studies. Boston MA: Applied Pharmaceutical Analysis 2007; 2007.
    1. Bansal S. Repeat bioanalysis selection and reporting. Arlington, VA: AAPS Workshop: Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays; 2006. - PubMed
    1. Rocci ML, Jr, Devanarayan V, Haughey DB, Jardieu P. Confirmatory reanalysis of incurred bioanalytical samples. AAPS Journal. 2007;9(3):E336–E343. doi: 10.1208/aapsj0903040. - DOI - PMC - PubMed
    1. Jemal M, Ouyang Z, Powell ML. A strategy for a post-method-validation use of incurred biological samples for establishing the acceptability of a liquid chromatography/tandem mass-spectrometric method for quantitation of drugs in biological samples. Rapid Commun Mass Spectrom. 2002;16:1538–1547. doi: 10.1002/rcm.757. - DOI - PubMed

Substances